▲ +62.57% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Curaleaf in the last 3 months. The average price target is $22.50, with a high forecast of $32.25 and a low forecast of $16.00. The average price target represents a 62.57% upside from the last price of $13.84.
The current consensus among 9 contributing investment analysts is to buy stock in Curaleaf. This Buy consensus rating has held steady for over two years.
Curaleaf Holdings, Inc. operates as an integrated medical and wellness cannabis operator in the United States. It operates in two segments, Cannabis Operations and Non-Cannabis Operations. The Cannabis Operations segment engages in the production and sale of cannabis through retail and wholesale channels. The Non-Cannabis Operations segment provides professional services, including cultivation, processing, and retail know-how and back office administration, intellectual property licensing, real estate leasing services, and lending facilities to medical and adult-use cannabis licensees under management service agreements. It offers oils for vaporizing, cartridges, tinctures, capsules, and ground-flower. The company also provides hemp-based CBD products. As of March 9, 2021, it operated 101 dispensaries, 23 cultivation sites, and 30 processing sites in 23 states of the United States. The company was founded in 2010 and is headquartered in Wakefield, Massachusetts.